在当前的研究中，通过水溶性自由基聚合反应，使用柚子籽黏液和β-环糊精基于pH调节的水凝胶，开发了一种能够维持卡培他滨释放模式并克服其剂量频率高、半衰期短和生物利用率低等缺点的药物载体。所开发的网络体系经历了热分析、傅里叶变换红外光谱、粉末X射线衍射、元素分析、扫描电子显微镜观察、平衡溶胀和体外释放调查等实验，以评估网络体系的稳定性、复合性、形态学和pH响应性能。结果显示，所形成的交联网络体系热稳定性良好且具有pH响应性。将含有卡培他滨的粘土纳米复合物引入膨胀的水凝胶中，制备了纳米复合水凝胶。所有配方在pH 7.4条件下具有从67.98%到92.98%不等的平衡溶胀度。水凝胶的最佳载药量为88.17%，而纳米复合水凝胶为74.27%。在经过研发的配方中，所有水凝胶的凝胶含量都在65.88%至93.56%之间。元素分析确认了卡培他滨成功地被纳入水凝胶中。在30小时后，纳米复合水凝胶的释放率比水凝胶高出80.02%。在口服药物动力学中，纳米复合水凝胶的t1/2（10.57小时）、AUC（121.52μg.h/ml）和MRT（18.95小时）均高于水凝胶。这些发现表明，pH响应性的载药体系可以提高卡培他滨的疗效并降低癌症治疗中的给药频率。毒性分析证明了该系统的安全性、无毒性和生物相容性。版权所有 © 2023 Elsevier B.V. 发布。

In current work, quince seed mucilage and β-Cyclodextrin based pH regulated hydrogels were developed using aqueous free radical polymerization to sustain Capecitabine release patterns and to overcome its drawbacks, such as high dose frequency, short half-life, and low bioavailability. Developed networks were subjected to thermal analysis, Fourier transforms infrared spectroscopy, powder x-ray diffraction, elemental analysis, scanning electron microscopy, equilibrium swelling, and in-vitro release investigations to assess the network system's stability, complexation, morphology, and pH responsiveness. Thermally stable pH-responsive cross-linked networks were formed. Nanocomposite hydrogels were prepared by incorporating Capecitabine-containing clay into the swollen hydrogels. All the formulations exhibited equilibrium swelling ranging from 67.98 % to 92.98 % at pH 7.4. Optimum Capecitabine loading (88.17 %) was noted in the case of hydrogels, while it was 74.27 % in nanocomposite hydrogels. Excellent gel content (65.88 %-93.56 %) was noticed among developed formulations. Elemental analysis ensured the successful incorporation of Capecitabine. Nanocomposite hydrogels released 80.02 % longer than hydrogels after 30 h. NC hydrogels had higher t1/2 (10.57 h), AUC (121.52 μg.h/ml), and MRT (18.95 h) than hydrogels in oral pharmacokinetics. These findings imply that the pH-responsive carrier system may improve Capecitabine efficacy and reduce dosing frequency in cancer therapy. Toxicity profiling proved the system's safety, non-toxicity, and biocompatibility.Copyright © 2023. Published by Elsevier B.V.